Moderna’s vaccine, easier to store 1:36
. – The Pfizer vaccine trial reached its safety milestone and the company is preparing to apply for an emergency use authorization, Pfizer CEO Albert Bourla said on Tuesday.
Pfizer announced on November 9 that its coronavirus vaccine appears to be more than 90% effective, based on early data.
But the company did not yet have enough data to apply for emergency use authorization from the US Food and Drug Administration, which said it also wanted at least two months of safety data on at least half of the volunteers. of a vaccine trial from the date they got their second immunization.
“I think questions about security in general have also been answered,” Bourla said in an interview with The New York Times. “Our safety milestone has already been achieved and we are now preparing for the presentations.”
Bourla said they are not yet sure how long their vaccine protection will last. The Pfizer vaccine uses a messenger RNA or mRNA platform to produce an immune response.
“With mRNA technology, you can boost as soon as you want,” Bourla said. People can receive an extra dose of a vaccine once immunity wears off, known as a booster.
Bourla said a booster, if needed, would likely require just one dose.
The 2 advantages of Moderna’s vaccine over Pfizer’s 0:50